Testing is available for locally advanced, non-resectable, or metastatic urothelial carcinoma using our Focus Panel amplicon-based targeted resequencing assay.
Predictive Testing
The Focus Panel can detect mutations and gene fusions in the following predictive genes:
- FGFR3 mutations: Predict response to erdafitinib
- FGFR2/3 gene fusions: Predict response to erdafitinib